Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amarantus Therapeutics, Inc.
CNS Protein Therapeutics Completes Name Change to Amarantus Therapeutics, Appoints New CEO Martin D. Cleary
November 10th, 2009
CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. ("Amarantus") and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer. Mr. Cleary succeeds Co-founder Gerald E. Commissiong, who has served as CEO since 2008. Mr. Commissiong, who will remain with Amarantus as Chief Business Officer, commented, "Derived from the Latin 'amarantus', our corporate name means 'one that does not wither'." The...
Source: Cardiovascular Business Week (2009-11-10)
|
